https://pubmed.ncbi.nlm.nih.gov/41410194/
Clinical and Molecular Effect of the Anti-IL-18 Antibody Aletekitug in Adults With Atopic Dermatitis
A single 2 mg/kg IV dose of aletekitug was associated with improved outcomes at Week 12, which were sustained to Week 24, and modulated immune mechanisms...